DrugPatentWatch Database Preview
Cytarabine - Generic Drug Details
What are the generic drug sources for cytarabine and what is the scope of cytarabine patent protection?
There are fifteen drug master file entries for cytarabine. Five suppliers are listed for this compound.
Summary for cytarabine
| US Patents: | 6 |
| Tradenames: | 4 |
| Applicants: | 9 |
| NDAs: | 17 |
| Drug Master File Entries: | 15 |
| Suppliers / Packagers: | 5 |
| Bulk Api Vendors: | 87 |
| Clinical Trials: | 931 |
| Patent Applications: | 7,531 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | cytarabine at DailyMed |
Pharmacology for cytarabine
| Drug Class | Nucleoside Metabolic Inhibitor |
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
Medical Subject Heading (MeSH) Categories for cytarabine
Synonyms for cytarabine
| (beta-D-Arabinofuranosyl)cytosine |
| (non-labelled)Cytarabine-13C-15N2 |
| 04079A1RDZ |
| 1-.beta.-D-arabinofuranosyl-cytosine |
| 1-(arabinofuranosyl)cytosine |
| 1-(b-D-Arabinofuranosyl)cytosine |
| 1-Arabinofuranosylcytosine |
| 1-beta -D-Arabinofaranosylcytosine |
| 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone |
| 1-beta -d-arabinofuranosylcytosine |
| 1-beta-arabinofuranosylcytosine |
| 1-beta-D-Arabinofaranosylcytosine |
| 1-beta-D-arabinofuranosyl cytosine |
| 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone |
| 1-beta-D-arabinofuranosyl-cytosine |
| 1-beta-D-Arabinofuranosylcytosine |
| 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside |
| 1-beta-D-Arabinosyl-Cytosine |
| 1-beta-D-Arabinosylcytosine |
| 10163-EP2272828A1 |
| 10163-EP2284920A1 |
| 10163-EP2287165A2 |
| 10163-EP2287166A2 |
| 10163-EP2292603A1 |
| 10163-EP2292620A2 |
| 10163-EP2298764A1 |
| 10163-EP2298765A1 |
| 10163-EP2298774A1 |
| 10163-EP2299509A1 |
| 10163-EP2301921A1 |
| 10163-EP2301926A1 |
| 10163-EP2301936A1 |
| 10163-EP2308843A1 |
| 10163-EP2314558A1 |
| 10163-EP2316452A1 |
| 10163-EP2371810A1 |
| 10163-EP2372804A1 |
| 10163-EP2378585A1 |
| 147-94-4 |
| 147C944 |
| 15153-EP2270018A1 |
| 15153-EP2272832A1 |
| 15153-EP2275420A1 |
| 15153-EP2277565A2 |
| 15153-EP2277566A2 |
| 15153-EP2277567A1 |
| 15153-EP2277568A2 |
| 15153-EP2277569A2 |
| 15153-EP2277570A2 |
| 15153-EP2277865A1 |
| 15153-EP2292280A1 |
| 15153-EP2295055A2 |
| 15153-EP2295416A2 |
| 15153-EP2295426A1 |
| 15153-EP2295427A1 |
| 15153-EP2298748A2 |
| 15153-EP2298764A1 |
| 15153-EP2298765A1 |
| 15153-EP2298768A1 |
| 15153-EP2298778A1 |
| 15153-EP2298780A1 |
| 15153-EP2301928A1 |
| 15153-EP2305642A2 |
| 15153-EP2305689A1 |
| 15153-EP2308833A2 |
| 15153-EP2308855A1 |
| 15153-EP2308861A1 |
| 15153-EP2311453A1 |
| 15153-EP2311808A1 |
| 15153-EP2311825A1 |
| 15153-EP2311829A1 |
| 15153-EP2311840A1 |
| 15153-EP2311842A2 |
| 15153-EP2314590A1 |
| 15153-EP2316832A1 |
| 15153-EP2316833A1 |
| 15187-EP2270008A1 |
| 15187-EP2280012A2 |
| 15187-EP2281815A1 |
| 15187-EP2292233A2 |
| 15187-EP2292615A1 |
| 15187-EP2292617A1 |
| 15187-EP2301928A1 |
| 15187-EP2301933A1 |
| 15187-EP2305640A2 |
| 15187-EP2305671A1 |
| 15187-EP2308833A2 |
| 15187-EP2311827A1 |
| 15187-EP2311840A1 |
| 15187-EP2316832A1 |
| 15187-EP2316833A1 |
| 1beta -Arabinofuranasylcytosine |
| 1beta -D-Arabinofuranosylcytosine |
| 1beta -D-Arabinosylcytosine |
| 1beta-Arabinofuranasylcytosine |
| 1beta-D-Arabinofuranosylcytosine |
| 1beta-D-Arabinosylcytosine |
| 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl |
| 2(1H)-Pyrimidinone, 4-amino-1-.beta.-D-arabinofuranosyl- |
| 2(1H)-Pyrimidinone, 4-amino-1-|A-D-arabinofuranosyl- |
| 2(1H)-Pyrimidinone, 4-amino-1-beta -D-arabinofuranosyl- |
| 2(1H)-Pyrimidinone, 4-amino-1-beta-D-arabinofuranosyl- |
| 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS] |
| 2(1H)-Pyrimidinone, 4-amino-1-y-D-arabinofuranosyl- [CAS] |
| 2(1H)-Pyrimidinone, 4-amino-1beta -D-arabinofuranosyl- |
| 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one |
| 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one |
| 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one |
| 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one |
| 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin |
| 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech] |
| 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine |
| 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone |
| 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon |
| 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech] |
| 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone |
| 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one |
| 69-74-9 (hydrochloride) |
| AB0005212 |
| AC-1075 |
| AC1L1M4F |
| AC1Q52OJ |
| AI3-52329 |
| AJ-45634 |
| AK-54744 |
| AKOS007930145 |
| AKOS015896896 |
| Alexan |
| AM84428 |
| ANW-58969 |
| AR3 |
| Ara-C |
| Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine |
| Ara-Cytidine |
| Arabinocytidine |
| arabinocytosine |
| Arabinofuranosylcytosine |
| Arabinoside C |
| Arabinosyl Cytosine |
| Arabinosylcytosine |
| Arabitin |
| AraC |
| Aracytidine |
| Aracytin |
| Aracytine |
| Arafcyt |
| AX8008499 |
| BDBM50087289 |
| beta -arabinosylcytosine |
| beta -cytosine arabinoside |
| beta -D-arabinosylcytosine |
| beta-Ara C |
| beta-Arabinosylcytosine |
| Beta-cytosine arabinoside |
| beta-D-Arabinosylcytosine |
| BIDD:GT0371 |
| BIDD:PXR0139 |
| BRD-K33106058-001-07-7 |
| BRD-K33106058-003-20-6 |
| BTB15125 |
| C-55053 |
| C02961 |
| C9H13N3O5 |
| CAS-147-94-4 |
| CCG-51297 |
| CCRIS 913 |
| CHEBI:28680 |
| CHEMBL803 |
| CHX 3311 |
| Citarabina |
| Citarabina [INN-Spanish] |
| CPD000449317 |
| CS-2177 |
| CTK8B7927 |
| Cyclocide |
| Cytarabin |
| Cytarabina |
| Cytarabine (JP15/USP/INN) |
| Cytarabine (JP17/USP/INN) |
| CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9) |
| Cytarabine [USAN:INN:BAN:JAN] |
| Cytarabine [USAN:USP:INN:BAN:JAN] |
| cytarabine liposome |
| cytarabine liposome injection |
| Cytarabine, European Pharmacopoeia (EP) Reference Standard |
| Cytarabine, United States Pharmacopeia (USP) Reference Standard |
| Cytarabine; 2(1H)-Pyrimidinone,4-amino-1-a-Darabinofuranosyl- |
| Cytarabinoside |
| Cytarabinum |
| Cytarabinum [INN-Latin] |
| Cytarbel |
| Cytartbine |
| Cytonal |
| Cytosar |
| Cytosar-U |
| Cytosar-U (TN) |
| Cytosine 1-beta-D-arabinofuranoside |
| Cytosine arabinofuranoside |
| Cytosine arabinose |
| Cytosine arabinoside |
| Cytosine arabinoside (VAN) |
| Cytosine beta-D-arabinofuranoside |
| Cytosine beta-D-arabinofuranoside hydrochloride |
| Cytosine beta-D-arabinofuranoside, crystalline, >=90% (HPLC) |
| Cytosine beta-D-arabinofuranoside, Vetec(TM) reagent grade, 90% |
| Cytosine beta-D-arabinoside |
| Cytosine-1-beta-D-arabinofuranoside |
| Cytosine-beta -arabinoside |
| Cytosine-beta -D-arabinofuranoside |
| Cytosine-beta-arabinoside |
| Cytosine-beta-D-arabinofuranoside |
| Cytosine, 1-beta -D-arabinofuranosyl- |
| Cytosine, 1-beta -D-arabinosyl- |
| Cytosine, 1-beta-D-arabinofuranosyl- |
| Cytosine, 1-beta-D-arabinosyl- |
| Cytosine, beta -D-arabinoside |
| Cytosine, beta-D-arabinoside |
| Cytosinearabinoside |
| D00168 |
| D07XSN |
| DB00987 |
| Depocyt |
| Depocyt (liposomal) |
| Depocyt (TN) |
| DepoCyte |
| DSSTox_CID_2877 |
| DSSTox_GSID_22877 |
| DSSTox_RID_76771 |
| DTXSID3022877 |
| EBD145460 |
| EINECS 205-705-9 |
| Erpalfa |
| FT-0082880 |
| FT-0624314 |
| GP6403 |
| GTPL4827 |
| HE003564 |
| HMS2051K19 |
| HMS2090A18 |
| HMS2230M16 |
| HSDB 3049 |
| HY-13605 |
| Intrathecal (injected into the spinal fluid) DepoCyt |
| Intrathecal cytarabine (also known as ara-C) |
| Iretin |
| J-520199 |
| J-700005 |
| J-700166 |
| J10463 |
| K-4708 |
| KB-09511 |
| KS-0000022L |
| KS-5063 |
| KSC917S2P |
| Lopac0_000316 |
| LS-860 |
| MCULE-3945147956 |
| MFCD00066487 |
| MK 8242 |
| MLS000758310 |
| MLS001066340 |
| MLS001424023 |
| MolPort-001-792-509 |
| NC00070 |
| NCGC00093356-03 |
| NCGC00093356-04 |
| NCGC00093356-05 |
| NCGC00093356-06 |
| NCGC00142483-02 |
| NCGC00255381-01 |
| NCI-C04728 |
| NSC 287459 |
| NSC287459 |
| NU006827 |
| PubChem14152 |
| PYR287 |
| RL01868 |
| s1648 |
| SAM001247012 |
| SCHEMBL3140 |
| SL-000002 |
| SMR000449317 |
| Spongocytidine |
| SR-01000075773-3 |
| SRI-10828_24 |
| SRI-10828-19 |
| SRI-10828-20 |
| ST24043183 |
| SY004943 |
| Tarabine |
| TL8001048 |
| Tox21_111203 |
| Tox21_301971 |
| TR-008148 |
| U 19920A |
| U-19,920 |
| U-19920 |
| Udicil |
| UHDGCWIWMRVCDJ-CCXZUQQUSA-N |
| UNII-04079A1RDZ |
| Z1522566619 |
| ZINC3795098 |
US Patents and Regulatory Information for cytarabine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 200914-001 | Dec 13, 2011 | AP | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;IV (INFUSION) | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Teva Pharms Usa | CYTOSAR-U | cytarabine | INJECTABLE;INJECTION | 075206-003 | Dec 30, 1998 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for cytarabine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Teva Parenteral | CYTARABINE | cytarabine | INJECTABLE;INJECTION | 016793-001 | Approved Prior to Jan 1, 1982 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Pacira Pharms Inc | DEPOCYT | cytarabine | INJECTABLE, LIPOSOMAL;INJECTION | 021041-001 | Apr 1, 1999 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Get our Free Drug Patent Bulletin
Join the 27,046 others who get our Drug Patent Expiration Alerts:
- Articles on vital topics
- Fresh industry trends
- Expiring drug patents
- More …
